Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Retigabine in Treating Weakness in a Mouse Model of Hypokalemic Periodic Paralysis.

Muscle & nerve - 1 Apr 2026

Denman Kirsten, Rich Mark M

Abstract excerpt

INTRODUCTION/AIMS: Hypokalemic periodic paralysis (HypoKPP) is an ion channelopathy causing episodic skeletal muscle weakness triggered by hypokalemia. Reduced inward rectifier K+ (Kir) channel activity contributes to membrane depolarization and paralysis, suggesting that pharmacologic activation of muscle K+ channels may restore excitability. The Kv7 channel agonist retigabine previously mitigated low-K+...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Hypokalemic Periodic Paralysis
Share to Muscle Contraction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle, Skeletal

Share to Muscle Weakness

Share to NAV1.4 Voltage-Gated Sodium Channel

Share to Phenylenediamines

Share to Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 41550072
DOI: 10.1002/mus.70158
PMCID: PMC12969955

Genes

SCN4A

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Retigabine in Treating Weakness in a Mouse Model of Hypokalemic Periodic Paralysis.PMID 41550072Read ↗

Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis.Semantic proximity Read ↗

Channelopathies of skeletal muscle excitability.Semantic proximity Read ↗

Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.Semantic proximity Read ↗

Semaglutide Reverses the Chronic Myopathy of Hyperkalemic Periodic Paralysis: A Case ReportSemantic proximity Read ↗

Mechanisms underlying the distinct K+ dependencies of periodic paralysis.Semantic proximity Read ↗

Voltage-Dependent Ca <sup>2+</sup> Release Is Impaired in Hypokalemic Periodic Paralysis Caused by Ca <sub>V</sub> 1.1-R528H but not by Na <sub>V</sub> 1.4-R669HSemantic proximity Read ↗

Contractile abnormalities of mouse muscles expressing hyperkalemic periodic paralysis mutant NaV1.4 channels do not correlate with Na+ influx or channel content.Semantic proximity Read ↗

A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis.Semantic proximity Read ↗

Thyrotoxic Hypokalemic Periodic Paralysis: Pathophysiological Mechanisms.Semantic proximity Read ↗

A calcium channel mutant mouse model of hypokalemic periodic paralysis.Semantic proximity Read ↗

Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness.Semantic proximity Read ↗

Periodic paralysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.